[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2018",
          "fs": "Aug 2018",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hmEbUAI"
          },
          "Id": "a0P2P000006hmEbUAI",
          "Event_Date__c": "2018-08-14",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Formatted_Date__c": "Aug 2018",
          "Status_History__c": "a132P000000Cw2vQAC"
        },
        "change": null
      }
    ],
    "dateString": "Aug 2018",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2019",
          "fs": "Feb 2019",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hmEcUAI"
          },
          "Id": "a0P2P000006hmEcUAI",
          "Event_Date__c": "2019-02-03",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Feb 2019",
          "Status_History__c": "a132P000000D4PLQA0"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<p><a href=\"https://pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf\" target=\"_blank\">PTAC minutes</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf\" target=\"_blank\">PTAC minutes</a></p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2019",
          "fs": "Feb 2019",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.",
          "fs": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hmGPUAY"
          },
          "Id": "a0P2P000006hmGPUAY",
          "Event_Date__c": "2019-02-21",
          "Event_Description__c": "Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<p><a href=\"https://pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf\" target=\"_blank\">PTAC minutes</a></p>",
          "Formatted_Date__c": "Feb 2019",
          "Status_History__c": "a132P000000D4QUQA0"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Oct 2019",
          "fs": "Oct 2019",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hmGQUAY"
          },
          "Id": "a0P2P000006hmGQUAY",
          "Event_Date__c": "2019-10-07",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Oct 2019",
          "Status_History__c": "a132P000000D4h8QAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": "<p><a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">CaTSoP Subcommittee minutes</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">CaTSoP Subcommittee minutes</a></p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Feb 2020",
          "fs": "Feb 2020",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.",
          "fs": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hmGRUAY"
          },
          "Id": "a0P2P000006hmGRUAY",
          "Event_Date__c": "2020-02-23",
          "Event_Description__c": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<p><a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">CaTSoP Subcommittee minutes</a></p>",
          "Formatted_Date__c": "Feb 2020",
          "Status_History__c": "a132P000000D4hfQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Apr 2021",
          "fs": "Apr 2021",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hmGSUAY"
          },
          "Id": "a0P2P000006hmGSUAY",
          "Event_Date__c": "2021-04-01",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Apr 2021",
          "Status_History__c": "a132P000000Cw2wQAC"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": "<p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The evidence for a PFS benefit with carfilzomib compared with bortezomib in this setting, and the evidence of an OS benefit in this setting from the ENDEAVOR trial; and</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That it was reasonable to extrapolate the benefits observed in the ENDEAVOR trial to the ARROW trial noting the different levels of prior treatment in these populations.<a href=\"\" target=\"_blank\" style=\"font-size: 8pt;\">[LH1]</a><span style=\"font-size: 8pt;\">\u00a0</span></p><p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee <b>recommended</b> that carfilzomib (once-weekly) for the third-line treatment of relapsed or refractory multiple myeloma be funded with a <b>medium</b> <b>priority</b>, in the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">CARFILZOMIB</b></p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Initial application</b><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\"> \u2013 (relapsed/refractory multiple myeloma) only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">All of the following:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">1.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Patient has relapsed or refractory multiple myeloma with progressive disease; and</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">2.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Patient has received two prior lines of treatment; and</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">3.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Treatment to be administered in combination with dexamethasone.</span></p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">\u00a0</b></p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Renewal</b><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\"> - (relapsed/refractory multiple myeloma) only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Both:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">1.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">No evidence of disease progression; and</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">2.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">The treatment remains appropriate and patient is benefitting from treatment.</span></p><p>1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>In making this recommendation, the Subcommittee considered</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The high health need of patients with relapsed/refractory multiple myeloma (including lenalidomide-refractory disease) requiring third-line treatment, however that the need for treatment in this setting was less than that in first relapse; and</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The evidence for a PFS benefit with carfilzomib compared with bortezomib in this setting, and the evidence of an OS benefit in this setting from the ENDEAVOR trial; and</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That it was reasonable to extrapolate the benefits observed in the ENDEAVOR trail to the ARROW trial noting the different levels of prior treatment in these populations.</p><p> </p>",
          "fs": "<p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The evidence for a PFS benefit with carfilzomib compared with bortezomib in this setting, and the evidence of an OS benefit in this setting from the ENDEAVOR trial; and</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That it was reasonable to extrapolate the benefits observed in the ENDEAVOR trial to the ARROW trial noting the different levels of prior treatment in these populations.<a href=\"\" target=\"_blank\" style=\"font-size: 8pt;\">[LH1]</a><span style=\"font-size: 8pt;\">\u00a0</span></p><p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee <b>recommended</b> that carfilzomib (once-weekly) for the third-line treatment of relapsed or refractory multiple myeloma be funded with a <b>medium</b> <b>priority</b>, in the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">CARFILZOMIB</b></p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Initial application</b><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\"> \u2013 (relapsed/refractory multiple myeloma) only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">All of the following:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">1.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Patient has relapsed or refractory multiple myeloma with progressive disease; and</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">2.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Patient has received two prior lines of treatment; and</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">3.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Treatment to be administered in combination with dexamethasone.</span></p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">\u00a0</b></p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Renewal</b><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\"> - (relapsed/refractory multiple myeloma) only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Both:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">1.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">No evidence of disease progression; and</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">2.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">The treatment remains appropriate and patient is benefitting from treatment.</span></p><p>1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>In making this recommendation, the Subcommittee considered</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The high health need of patients with relapsed/refractory multiple myeloma (including lenalidomide-refractory disease) requiring third-line treatment, however that the need for treatment in this setting was less than that in first relapse; and</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The evidence for a PFS benefit with carfilzomib compared with bortezomib in this setting, and the evidence of an OS benefit in this setting from the ENDEAVOR trial; and</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That it was reasonable to extrapolate the benefits observed in the ENDEAVOR trail to the ARROW trial noting the different levels of prior treatment in these populations.</p><p> </p>",
          "change": null
        },
        "Published_Discussion": {
          "s": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that, based on real-world clinical practice, almost all patients with multiple myeloma will receive first-line treatment although only about 61% and 38% of patients will receive second- and third-line treatments, respectively. </p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the possible second-line treatment options consisted of bortezomib retreatment (as CyBorD/BTD) or bortezomib in combination with melphalan and prednisone (BMP) and that it was preferable to expose patients to new agents than retreating with bortezomib. Alternatively, patients would receive a thalidomide-based regimen, which would consist of cyclophosphamide, thalidomide and dexamethasone (CTD) or melphalan, prednisone and thalidomide (MPT), all for approximately six to 12 cycles. The Subcommittee noted that patients could be eligible for lenalidomide in combination with dexamethasone until progression if neuropathy prevents use of bortezomib and thalidomide-based regimens. The Subcommittee noted that in patients with relapsed/refractory multiple myeloma, if remission was for greater than two to three years, and the patient was transplant eligible, a second autologous stem cell transplant would be offered.</p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the choice of second-line regimen would be determined by the duration of response to first-line treatment, toxicities experienced in the first-line, and patient-specific factors including the desire for oral therapy.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that once a patient progresses after second line therapy, if they had received an autologous stem cell transplant with lenalidomide maintenance there are no further options for this patient group. The Subcommittee noted that lenalidomide with dexamethasone with or without bortezomib was a third-line treatment option, only for transplant-ineligible patients who had not received lenalidomide maintenance post autologous stem cell transplant. </p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee was made aware of data reporting progression-free survival (PFS) of around eight months with bortezomib retreatment in relapsed multiple myeloma, from two clinical trials, and considered the efficacy of bortezomib retreatment after first-line bortezomib to be limited: </p><p><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>A 6.5-month duration of response was reported in 130 patients who received bortezomib with or without dexamethasone after median two prior lines of therapy (<a href=\"https://doi.org/10.1111/bjh.12198\" target=\"_blank\">Petrucci et al. Br J Haematol. 2013;160:649-59</a>); and </p><p><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>In the CASTOR trial control arm of bortezomib and dexamethasone (N = 113), median PFS was 7.1 months and median PFS in patients who had received one prior line of therapy was 7.9 months. About 45% of patients had received one prior line, and about 70% of patients had prior bortezomib exposure (<a href=\"http://www.haematologica.org/content/103/12/2079.long\" target=\"_blank\">Spencer et al. Haematologica. 2018;103:2079-87</a>).</p><p><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the duration of benefit from thalidomide in the second-line setting was hard to estimate, as clinical trials generally allow use of agents at relapse that are less comparable to the New Zealand setting, however, noted that thalidomide is associated with relatively short PFS and toxicities including neuropathy which limit its use. The Subcommittee considered it reasonable to assume that outcomes would be similar to that observed in patients retreated with bortezomib.</p><p><span style=\"color: black;\">1.7.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee was made aware of evidence that a significant number of patients (about 50%) progress on lenalidomide maintenance and have few subsequent treatment options, as they are unlikely to receive a response from thalidomide and early relapse after prior bortezomib treatment makes its use in retreatment less likely to be successful (<a href=\"https://ashpublications.org/blood/article/134/Supplement_1/1779/427686/Outcomes-in-Multiple-Myeloma-Patients-Progressing\" target=\"_blank\">Sanchez et al. Blood. 2019;134(Suppl_1):1779</a>). </p><p><span style=\"color: black;\">1.8.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that in New Zealand the second-line treatment options provide suboptimal benefits and that there is a definite need for more effective second-line treatment for multiple myeloma including lenalidomide-refractory patients. The Subcommittee considered the unmet need for treatments in later lines of therapy was also high, but that the number of patients requiring treatment in this context was less, and that there would be a proportion of patients who would remain eligible for lenalidomide-based treatment in this setting.</p><p><span style=\"color: black;\">1.9.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that multiple myeloma treatment is evolving internationally with use of other combinations and other treatments, and was made aware of international clinical guidelines that recommend second-line treatments or combinations that are not funded in New Zealand (<a href=\"https://jnccn.org/doi/10.6004/jnccn.2018.0002\" target=\"_blank\">Kumar et al. J Natl Compr Canc Netw. 2018;16:11-20</a>; <a href=\"https://linkinghub.elsevier.com/retrieve/pii/3768071\" target=\"_blank\">Moreau et al. Ann Oncol. 2017;28(suppl_4):iv52-iv61</a>). The Subcommittee noted that some of the potential treatments that could be used by patients with relapsed/refractory multiple myeloma include, but are not limited to carfilzomib, ixazomib, pomalidomide, daratumumab and elotuzumab.</p><p><span style=\"color: black;\">1.10.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that the New Zealand Myeloma Interest Group (NZMIG) has expressed its preference for daratumumab (especially if subcutaneous) and carfilzomib, which the NZMIG consider very effective, to be funded for the treatment of relapsed/refractory multiple myeloma. However, the Subcommittee noted that Pharmac sought advice at this time regarding carfilzomib and pomalidomide in the context of currently funded treatments (ie without consideration of unfunded treatments such as daratumumab).<a href=\"\" target=\"_blank\" style=\"font-size: 8pt;\">[LH1]</a><span style=\"font-size: 8pt;\">\u00a0</span></p><p><i>Carfilzomib</i></p><p><span style=\"color: black;\">1.11.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that it had previously reviewed an application for carfilzomib in the relapsed/refractory setting in <a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">October 2019</a> following PTAC\u2019s review of the application in <a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf\" target=\"_blank\">February 2019</a>. The Subcommittee noted that carfilzomib is an intravenously-administered proteasome inhibitor and that Medsafe has approved carfilzomib (Kyprolis) in combination with either lenalidomide and dexamethasone, or dexamethasone alone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. The Subcommittee noted that the Medsafe data sheet lists the following recommended dosing regimens for carfilzomib in this setting: </p><p>1.11.1.<span style=\"font-size: 7pt;\"> </span>Carfilzomib (with dexamethasone) administered as a 20 mg/m<sup>2</sup> starting dose, then on cycle 1 day 8, if tolerated, carfilzomib dose increased to 70 mg/m<sup>2</sup> once weekly (30-minute infusion); and</p><p>1.11.2.<span style=\"font-size: 7pt;\"> </span>Carfilzomib (with dexamethasone and lenalidomide) administered as a 20 mg/m<sup>2</sup> starting dose, then on cycle 1 day 8, if tolerated, carfilzomib dose increased to 27 mg/m<sup>2</sup> twice weekly (10-minute infusion) or 56 mg/m<sup>2</sup> twice weekly (30-minute infusion).</p><p><span style=\"color: black;\">1.12.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that international funding bodies in Australia, Canada, England and Wales, and Scotland have recommended carfilzomib in combination with dexamethasone be funded for second-line use (and for third-line use in Canada). The Subcommittee noted that the once-weekly regimen is funded in Australia for patients with relapsed/refractory multiple myeloma.</p><p>Evidence for carfilzomib with dexamethasone (second-line and third-line) </p><p><span style=\"color: black;\">1.13.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that evidence for twice-weekly carfilzomib comes from the randomised (1:1), phase III, open-label, multicentre ENDEAVOR trial of 929 patients with relapsed or refractory multiple myeloma (<a href=\"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00464-7/fulltext\" target=\"_blank\">Dimopoulos et al. Lancet Oncol. 2016;17:27-38</a>). The Subcommittee noted that the median age of ENDEAVOR participants was 65 years and considered this group was slightly younger than New Zealand patient population who are about 70 years at diagnosis. The Subcommittee noted that participants had one to three (median two) prior lines of therapy, with half of participants in each group having received two or three prior lines, and 54% of participants having previously received bortezomib.</p><p>1.13.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that participants received carfilzomib 56 mg/m<sup>2 </sup>twice weekly (20 mg/m<sup>2</sup> on days one and two of cycle one; 56 mg/m<sup>2</sup> thereafter) with dexamethasone (20 mg oral or intravenous [IV] infusion) or bortezomib (1.3 mg/m<sup>2</sup>; IV bolus or subcutaneous [SC] injection) with dexamethasone as 28-day cycles continued until disease progression. The Subcommittee noted that this dosing was one of the Medsafe-approval regimens and considered that the bortezomib comparator treatment was a relevant treatment option in the New Zealand setting, although triple therapy may also be used. </p><p>1.13.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the primary endpoint was progression-free survival (PFS) in the intention-to-treat population, which was a median 18.7 months (95% CI 15.6\u2013not estimable) with carfilzomib versus 9.4 months (8.4\u201310.4) with bortezomib (hazard ratio, HR 0.53; 95% CI: 0.44 to 0.65; P&lt;0.0001). The Subcommittee noted that PFS in patients previously exposed to bortezomib was 15.6 months (12.9 to not evaluable) with carfilzomib vs 8.1 months (6.6 to 9.5) with bortezomib. The Subcommittee considered that the outcomes in the control arm of this trial were indicative of the outcomes that could be expected with bortezomib retreatment.</p><p>1.13.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that carfilzomib was favoured over bortezomib retreatment in all patient subgroups except patients with disease refractory to prior bortezomib or lenalidomide, although there were small patient numbers in those groups.</p><p>1.13.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the pre-planned interim overall survival (OS) analysis was performed at cut-off date Jan 3, 2017, at which time the median OS was 47.6 months (95% CI 42.5-not evaluable) with carfilzomib versus 40.0 months (32.6-42.3) in the bortezomib group (HR 0.791 [95% CI 0.648-0.964], one-sided <i>P</i>=0.010) (<a href=\"https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(17)30578-8\" target=\"_blank\">Dimopoulos et al. Lancet Oncol. 2017;18:1327-37</a>). The Subcommittee noted that there was less OS benefit in patients over 75 years of age, those with renal impairment (creatine clearance &lt;30 mL/min) and those with high-risk cytogenetics.</p><p><span style=\"color: black;\">1.14.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that evidence for once-weekly carfilzomib comes from the randomised (1:1), open-label, phase III ARROW trial of 578 patients with relapsed and refractory multiple myeloma with measurable disease who had received two or three prior treatments (including a proteasome inhibitor and immunomodulatory imide drug ie lenalidomide or thalidomide) (<a href=\"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext\" target=\"_blank\">Moreau et al. Lancet Oncol. 2018;19:953-64</a>). The Subcommittee noted that the ARROW population were more heavily pre-treated and disease-refractory than the ENDEAVOR population.</p><p><br></p><p>1.14.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that participants received carfilzomib 70 mg/m<sup>2</sup> once weekly (20 mg/m\u00b2 day 1 cycle 1; 70 mg/m\u00b2 thereafter) or carfilzomib 27 mg/m<sup>2</sup> twice weekly (20 mg/m\u00b2 days 1 and 2 during cycle 1; 27 mg/m\u00b2 thereafter). The Subcommittee noted that all patients received dexamethasone 40 mg on days 1, 8, 15 (all cycles) and 22 (cycles 1\u20139 only) and that the 28-day treatment cycles continued until disease progression or unacceptable toxicity.</p><p>1.14.2.<span style=\"font-size: 7pt;\"> </span>The Subcommittee considered that the lower dose carfilzomib comparator was less relevant and that a twice weekly standard dose (ie 56 mg/m<sup>2</sup> twice weekly as per ENDEAVOR and Medsafe approved dose) would have been more relevant to the New Zealand population.</p><p>1.14.3.<span style=\"font-size: 7pt;\"> </span>The Subcommittee noted that the primary endpoint was PFS in the intention-to-treat population, which was median 11.2 months (95% CI 8.6 to 13.0) with 70 mg/m<sup>2</sup> once weekly vs 7.6 months (95% CI: 5.8 to 9.2) with 27 mg/m<sup>2</sup> twice weekly (HR 0.69, 95% CI: 0.54 to 0.83; <i>P</i>=0.0029).</p><p>1.14.4.<span style=\"font-size: 7pt;\"> </span>The Subcommittee noted that median PFS was greater with 56 mg/m<sup>2</sup> twice-weekly in ENDEAVOR (18.7 months) than with 70 mg/m<sup>2</sup> once-weekly in ARROW (11.3 months), however, data with propensity score adjustment suggested there was more benefit with the ARROW regimen (median PFS 21.0 months) compared with ENDEAVOR (14.9 months). The Subcommittee noted that, due to the lack of non-inferiority or superiority testing, CaTSoP previously considered in <a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">October 2019</a> that these high-dose once-weekly and twice-weekly regimens likely provided comparable PFS benefits. </p><p>1.14.5.<span style=\"font-size: 7pt;\"> </span>The Subcommittee considered it likely that a population with fewer prior lines of treatment (eg more akin to the ENDEAVOR population) would receive a greater PFS benefit than that reported for ARROW participants from the once-weekly 70 mg/m<sup>2</sup> ARROW regimen.</p><p><span style=\"color: black;\">1.15.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted further evidence of once-weekly carfilzomib dosing comes from the abstract of a phase II trial (GEM-KyCyDex) presented at the December 2020 ASH conference <a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\" style=\"color: windowtext;\">(</a><a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\">Mateos et al. 415 Paper presented at: American Society of Haematology Annual Meeting; December 2020</a><a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\" style=\"color: windowtext;\">).</a><a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\" style=\"color: rgb(0, 176, 80);\"> </a>The Subcommittee noted that 198 participants received carfilzomib 70mg/m<sup>2</sup> (days 1,8,15) and dexamethasone 20mg (days 1,8,15) with or without cyclophosphamide IV 300mg/m2 (days 1,8, 15).</p><p>1.15.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the median age was 70 years and that 61% of participants received one prior line of treatment. The Subcommittee noted that all patients had previously been treated with bortezomib, that about 90% responded to bortezomib treatment and approximately 70% had been previously treated with lenalidomide, half of who had refractory disease. </p><p>1.15.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the reporting that after median follow-up of 15.6 months, median PFS was 20.7 months with carfilzomib, dexamethasone and cyclophosphamide vs 15.2 months carfilzomib and dexamethasone (<i>P</i>=0.2). The Subcommittee considered that it was expected that cyclophosphamide would add benefit, especially in <span style=\"color: black;\">immunomodulatory imide drug</span>-refractory patients where there was a significant benefit in PFS (26.2 months vs 7.7 months; <i>P</i>=0.01). The Subcommittee considered that this supported the evidence of effect from once-weekly carfilzomib in the ARROW trial. </p><p>\tEvidence for carfilzomib with dexamethasone and lenalidomide (second-line) </p><p><span style=\"color: black;\">1.16.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted evidence from the randomised (1:1), open-label, multicentre, phase III ASPIRE study, which included 792 patients with relapsed multiple myeloma with measurable disease (<a href=\"https://www.nejm.org/doi/10.1056/NEJMoa1411321?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov\" target=\"_blank\">Stewart et al. N Engl J Med. 2015;372:142-52</a>; <a href=\"https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7\" target=\"_blank\">Dimopoulos et al. J Hematol Oncol. 2018;11:49</a>). The Subcommittee noted that 43% of participants had received one prior line of therapy and 65% had two to three prior lines. The Subcommittee noted that 65% of participants had received prior bortezomib and 20% prior lenalidomide, although the trial did not include patients who were refractory to these agents. </p><p>1.16.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that participants received carfilzomib twice weekly (20 mg/m<sup>2</sup> days 1 and 2 of cycle 1; 27 mg/m<sup>2</sup> thereafter until progression or unacceptable toxicity; omitted on D8 and D9 during cycles 13 to 18; and discontinued after 18 cycles) with lenalidomide (25 mg days 1-21) and dexamethasone (40 mg days 1, 8, 15 and 22) or lenalidomide with dexamethasone (control group) according to the same dosing. </p><p>1.16.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the primary endpoint was PFS in the intention-to-treat population, which was median 26.3 months (95% CI: 23.3 to 30.5) with carfilzomib vs 17.6 months (95% CI: 15.0 to 20.6) in the control group (HR for progression or death, 0.69; 95% CI, 0.57 to 0.83; <i>P</i>=0.0001).</p><p>1.16.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that this evidence indicates a benefit from carfilzomib in the carfilzomib group with lenalidomide and that hazard ratios for PFS in subgroups suggest most subgroups appear to benefit from treatment (eg according to number of prior lines, prior bortezomib use or not). The Subcommittee considered that this data suggests the carfilzomib regimen could be considered effective in the second-line or third-line setting.</p><p>Summary</p><p><span style=\"color: black;\">1.17.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee considered that the evidence supporting a benefit of carfilzomib for patients with relapsed/refractory multiple myeloma was stronger for patients who had received only one prior line of treatment, compared with patients with multiply relapsed disease. The Subcommittee also considered that the unmet need for patients at initial relapse was greater, given the current treatment options available, than the unmet need in multiply relapsed patients.</p><p><span style=\"color: black;\">1.18.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that quality of life (QOL) from the addition of carfilzomib in ENDEAVOR treatment was similar to QOL with bortezomib and dexamethasone (<a href=\"https://www.nature.com/articles/s41408-019-0181-0\" target=\"_blank\">Ludwig et al. Blood Cancer J. 2019;9:23</a>); that QOL data in ARROW indicated a preference for once-weekly treatment (<a href=\"https://www.nature.com/articles/s41375-019-0480-2\" target=\"_blank\">Moreau et al. Leukemia. 2019;33:2934-46</a>); and that ASPIRE suggested that QOL with carfilzomib, lenalidomide and dexamethasone was as good or better than QOL with lenalidomide and dexamethasone alone (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27601539/\" target=\"_blank\">Stewart et al. J Clin Oncol. 2016;34:3921-30</a>). The Subcommittee considered all carfilzomib QOL outcomes were similar, indicating that carfilzomib is well tolerated, that it does not negatively impact quality of life, and that weekly dosing is preferred. </p><p><span style=\"color: black;\">1.19.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that there was no direct comparative evidence for carfilzomib 70 mg/m<sup>2</sup> once weekly vs 56 mg/m<sup>2</sup> twice weekly, and that it was reasonable to assume that the differences between ENDEAVOR and ARROW patients reflect the extent of pre-treatment in these groups. The Subcommittee considered that the evidence for carfilzomib once-weekly and twice-weekly dosing was of good strength and quality. Overall, the Subcommittee considered this evidence suggests carfilzomib once weekly would provide benefits in the second-line and in the third-line setting, and that the evidence from ENDEAVOR and ASPIRE suggests the benefit would be across all subgroups with relapsed/refractory MM (although there would be smaller benefit in lenalidomide-refractory disease). </p><p><span style=\"color: black;\">1.20.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that the higher carfilzomib doses given once weekly were equivalent to dosing of 70 mg/m2 and 112 mg/m2 per week and that these regimens are used in some jurisdictions (registered in USA and Switzerland; being considered by TGA and Canada). The Subcommittee considered it reasonable to infer that efficacy is probably similar between these two dosing regimens and that risks may be similar, although weekly treatment may be slightly better tolerated. </p><p><span style=\"color: black;\">1.21.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee considered that, if funded as a second-line or third-line treatment, carfilzomib and dexamethasone could be administered either according to the ENDEAVOR trial dosing (56 mg/m<sup>2</sup> twice weekly) or the ARROW trial dosing (70 mg/m<sup>2</sup> once weekly) until disease progression. The Subcommittee noted that in <a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">October 2019</a> CaTSoP had thought that the uptake of 70 mg/m<sup>2</sup> once weekly would be low, given uncertainty of benefit. The Subcommittee considered that the updated publication with evidence of impact from once-weekly dosing, along with the submission from the NZMIG indicating that this dosing regimen would be preferred by New Zealand clinicians, suggests that once-weekly may be preferred due to its lesser impact on infusion resources. The Subcommittee considered that the higher weekly dosing may be used in patients who find the twice-weekly treatment challenging eg due to travel requirements and infusion burden.</p><p><span style=\"color: black;\">1.22.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee considered that it would be reasonable to assume that the outcomes observed with twice-weekly carfilzomib in the ENDEAVOR trial would be similar if these patients had received the once-weekly dosing regimen used in the ARROW trial. The Subcommittee therefore considered that it would be reasonable to use the outcomes from each trial as a surrogate for the benefit of carfilzomib-based therapy at initial relapse or in multiply relapsed patients.</p><p> </p><p><i>General</i></p><p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that there was no randomised controlled trial evidence comparing second-line treatment options against each other (ie carfilzomib vs pomalidomide) therefore evidence was lacking to inform preferred treatment sequencing. However, the Subcommittee considered that there would be a preference for carfilzomib to be used second-line, with pomalidomide reserved for third-line or later use. The Subcommittee noted that it will consider an <a href=\"https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000BD0yw/p001671\" target=\"_blank\">application for subcutaneous daratumumab</a> at a future meeting and that the Subcommittee could again indicate the preferred treatment options for this population at that time.\u00a0</p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that it would be reasonable to target funding via Special Authority criteria to enable carfilzomib and pomalidomide each to be used once per patient lifetime, or to be used in pre-specified treatment lines, as supported by evidence.</p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the estimate that 50% of patients with multiple myeloma may be eligible for transplant. However, the Subcommittee considered this estimate was likely too high for second- or third-line patients, as transplant eligibility decreases over time given the age of patients at initial diagnosis. The Subcommittee considered that in time, the funded use of lenalidomide in the relapsed/refractory setting would be indicative of the proportion of patients who are ineligible for transplant in third-line setting. The Subcommittee noted that there are approximately 400 patients diagnosed with multiple myeloma each year and considered that approximately 50% would initially be eligible for transplant. The Subcommittee considered that on this basis there would be approximately 130 patients who would relapse post-transplant each year; that there would be approximately 150 patients who would relapse after first line treatment if ineligible for transplant each year; and there would be approximately 170 patients who would require treatment in the third line setting each year.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the number of cycles received will depend on PFS which is influenced by prior lines of therapy and the proportion of patients whose disease was refractory, therefore the treatment cost per cycle would be most useful for cost-effectiveness assessment, as opposed to cost per treatment, given the variable extent of pre-treatment in the clinical trials.</p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that for second-line treatment, comparators could be bortezomib retreatment as CyBorD/BTD, or MPT and CTD. The Subcommittee considered that the key outcome of interest in this setting was improved PFS (above that gained from bortezomib retreatment). The Subcommittee considered the most appropriate comparator for use in the second-line would be BTD, unless the patient could not tolerate bortezomib, in which case regimens without bortezomib would be used. The Subcommittee considered that the efficacy of thalidomide in this setting is limited by the development of neuropathy, and efficacy difficult to establish from the scientific evidence base as most studies use more novel agents at relapse. The Subcommittee considered that outcomes would be expected to be worse without bortezomib.</p><p><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that for third-line treatment, standard therapy is lenalidomide and dexamethasone with or without bortezomib, although patients who had a prior autologous stem cell transplant with lenalidomide maintenance could be considered for third-line treatment with a bortezomib and/or thalidomide-based regimen. The Subcommittee considered that the key outcomes of interest in this setting were improved PFS and OS. </p><h2><br></h2>",
          "fs": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that, based on real-world clinical practice, almost all patients with multiple myeloma will receive first-line treatment although only about 61% and 38% of patients will receive second- and third-line treatments, respectively. </p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the possible second-line treatment options consisted of bortezomib retreatment (as CyBorD/BTD) or bortezomib in combination with melphalan and prednisone (BMP) and that it was preferable to expose patients to new agents than retreating with bortezomib. Alternatively, patients would receive a thalidomide-based regimen, which would consist of cyclophosphamide, thalidomide and dexamethasone (CTD) or melphalan, prednisone and thalidomide (MPT), all for approximately six to 12 cycles. The Subcommittee noted that patients could be eligible for lenalidomide in combination with dexamethasone until progression if neuropathy prevents use of bortezomib and thalidomide-based regimens. The Subcommittee noted that in patients with relapsed/refractory multiple myeloma, if remission was for greater than two to three years, and the patient was transplant eligible, a second autologous stem cell transplant would be offered.</p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the choice of second-line regimen would be determined by the duration of response to first-line treatment, toxicities experienced in the first-line, and patient-specific factors including the desire for oral therapy.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that once a patient progresses after second line therapy, if they had received an autologous stem cell transplant with lenalidomide maintenance there are no further options for this patient group. The Subcommittee noted that lenalidomide with dexamethasone with or without bortezomib was a third-line treatment option, only for transplant-ineligible patients who had not received lenalidomide maintenance post autologous stem cell transplant. </p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee was made aware of data reporting progression-free survival (PFS) of around eight months with bortezomib retreatment in relapsed multiple myeloma, from two clinical trials, and considered the efficacy of bortezomib retreatment after first-line bortezomib to be limited: </p><p><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>A 6.5-month duration of response was reported in 130 patients who received bortezomib with or without dexamethasone after median two prior lines of therapy (<a href=\"https://doi.org/10.1111/bjh.12198\" target=\"_blank\">Petrucci et al. Br J Haematol. 2013;160:649-59</a>); and </p><p><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>In the CASTOR trial control arm of bortezomib and dexamethasone (N = 113), median PFS was 7.1 months and median PFS in patients who had received one prior line of therapy was 7.9 months. About 45% of patients had received one prior line, and about 70% of patients had prior bortezomib exposure (<a href=\"http://www.haematologica.org/content/103/12/2079.long\" target=\"_blank\">Spencer et al. Haematologica. 2018;103:2079-87</a>).</p><p><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the duration of benefit from thalidomide in the second-line setting was hard to estimate, as clinical trials generally allow use of agents at relapse that are less comparable to the New Zealand setting, however, noted that thalidomide is associated with relatively short PFS and toxicities including neuropathy which limit its use. The Subcommittee considered it reasonable to assume that outcomes would be similar to that observed in patients retreated with bortezomib.</p><p><span style=\"color: black;\">1.7.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee was made aware of evidence that a significant number of patients (about 50%) progress on lenalidomide maintenance and have few subsequent treatment options, as they are unlikely to receive a response from thalidomide and early relapse after prior bortezomib treatment makes its use in retreatment less likely to be successful (<a href=\"https://ashpublications.org/blood/article/134/Supplement_1/1779/427686/Outcomes-in-Multiple-Myeloma-Patients-Progressing\" target=\"_blank\">Sanchez et al. Blood. 2019;134(Suppl_1):1779</a>). </p><p><span style=\"color: black;\">1.8.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that in New Zealand the second-line treatment options provide suboptimal benefits and that there is a definite need for more effective second-line treatment for multiple myeloma including lenalidomide-refractory patients. The Subcommittee considered the unmet need for treatments in later lines of therapy was also high, but that the number of patients requiring treatment in this context was less, and that there would be a proportion of patients who would remain eligible for lenalidomide-based treatment in this setting.</p><p><span style=\"color: black;\">1.9.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that multiple myeloma treatment is evolving internationally with use of other combinations and other treatments, and was made aware of international clinical guidelines that recommend second-line treatments or combinations that are not funded in New Zealand (<a href=\"https://jnccn.org/doi/10.6004/jnccn.2018.0002\" target=\"_blank\">Kumar et al. J Natl Compr Canc Netw. 2018;16:11-20</a>; <a href=\"https://linkinghub.elsevier.com/retrieve/pii/3768071\" target=\"_blank\">Moreau et al. Ann Oncol. 2017;28(suppl_4):iv52-iv61</a>). The Subcommittee noted that some of the potential treatments that could be used by patients with relapsed/refractory multiple myeloma include, but are not limited to carfilzomib, ixazomib, pomalidomide, daratumumab and elotuzumab.</p><p><span style=\"color: black;\">1.10.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that the New Zealand Myeloma Interest Group (NZMIG) has expressed its preference for daratumumab (especially if subcutaneous) and carfilzomib, which the NZMIG consider very effective, to be funded for the treatment of relapsed/refractory multiple myeloma. However, the Subcommittee noted that Pharmac sought advice at this time regarding carfilzomib and pomalidomide in the context of currently funded treatments (ie without consideration of unfunded treatments such as daratumumab).<a href=\"\" target=\"_blank\" style=\"font-size: 8pt;\">[LH1]</a><span style=\"font-size: 8pt;\">\u00a0</span></p><p><i>Carfilzomib</i></p><p><span style=\"color: black;\">1.11.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that it had previously reviewed an application for carfilzomib in the relapsed/refractory setting in <a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">October 2019</a> following PTAC\u2019s review of the application in <a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf\" target=\"_blank\">February 2019</a>. The Subcommittee noted that carfilzomib is an intravenously-administered proteasome inhibitor and that Medsafe has approved carfilzomib (Kyprolis) in combination with either lenalidomide and dexamethasone, or dexamethasone alone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. The Subcommittee noted that the Medsafe data sheet lists the following recommended dosing regimens for carfilzomib in this setting: </p><p>1.11.1.<span style=\"font-size: 7pt;\"> </span>Carfilzomib (with dexamethasone) administered as a 20 mg/m<sup>2</sup> starting dose, then on cycle 1 day 8, if tolerated, carfilzomib dose increased to 70 mg/m<sup>2</sup> once weekly (30-minute infusion); and</p><p>1.11.2.<span style=\"font-size: 7pt;\"> </span>Carfilzomib (with dexamethasone and lenalidomide) administered as a 20 mg/m<sup>2</sup> starting dose, then on cycle 1 day 8, if tolerated, carfilzomib dose increased to 27 mg/m<sup>2</sup> twice weekly (10-minute infusion) or 56 mg/m<sup>2</sup> twice weekly (30-minute infusion).</p><p><span style=\"color: black;\">1.12.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that international funding bodies in Australia, Canada, England and Wales, and Scotland have recommended carfilzomib in combination with dexamethasone be funded for second-line use (and for third-line use in Canada). The Subcommittee noted that the once-weekly regimen is funded in Australia for patients with relapsed/refractory multiple myeloma.</p><p>Evidence for carfilzomib with dexamethasone (second-line and third-line) </p><p><span style=\"color: black;\">1.13.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that evidence for twice-weekly carfilzomib comes from the randomised (1:1), phase III, open-label, multicentre ENDEAVOR trial of 929 patients with relapsed or refractory multiple myeloma (<a href=\"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00464-7/fulltext\" target=\"_blank\">Dimopoulos et al. Lancet Oncol. 2016;17:27-38</a>). The Subcommittee noted that the median age of ENDEAVOR participants was 65 years and considered this group was slightly younger than New Zealand patient population who are about 70 years at diagnosis. The Subcommittee noted that participants had one to three (median two) prior lines of therapy, with half of participants in each group having received two or three prior lines, and 54% of participants having previously received bortezomib.</p><p>1.13.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that participants received carfilzomib 56 mg/m<sup>2 </sup>twice weekly (20 mg/m<sup>2</sup> on days one and two of cycle one; 56 mg/m<sup>2</sup> thereafter) with dexamethasone (20 mg oral or intravenous [IV] infusion) or bortezomib (1.3 mg/m<sup>2</sup>; IV bolus or subcutaneous [SC] injection) with dexamethasone as 28-day cycles continued until disease progression. The Subcommittee noted that this dosing was one of the Medsafe-approval regimens and considered that the bortezomib comparator treatment was a relevant treatment option in the New Zealand setting, although triple therapy may also be used. </p><p>1.13.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the primary endpoint was progression-free survival (PFS) in the intention-to-treat population, which was a median 18.7 months (95% CI 15.6\u2013not estimable) with carfilzomib versus 9.4 months (8.4\u201310.4) with bortezomib (hazard ratio, HR 0.53; 95% CI: 0.44 to 0.65; P&lt;0.0001). The Subcommittee noted that PFS in patients previously exposed to bortezomib was 15.6 months (12.9 to not evaluable) with carfilzomib vs 8.1 months (6.6 to 9.5) with bortezomib. The Subcommittee considered that the outcomes in the control arm of this trial were indicative of the outcomes that could be expected with bortezomib retreatment.</p><p>1.13.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that carfilzomib was favoured over bortezomib retreatment in all patient subgroups except patients with disease refractory to prior bortezomib or lenalidomide, although there were small patient numbers in those groups.</p><p>1.13.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the pre-planned interim overall survival (OS) analysis was performed at cut-off date Jan 3, 2017, at which time the median OS was 47.6 months (95% CI 42.5-not evaluable) with carfilzomib versus 40.0 months (32.6-42.3) in the bortezomib group (HR 0.791 [95% CI 0.648-0.964], one-sided <i>P</i>=0.010) (<a href=\"https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(17)30578-8\" target=\"_blank\">Dimopoulos et al. Lancet Oncol. 2017;18:1327-37</a>). The Subcommittee noted that there was less OS benefit in patients over 75 years of age, those with renal impairment (creatine clearance &lt;30 mL/min) and those with high-risk cytogenetics.</p><p><span style=\"color: black;\">1.14.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that evidence for once-weekly carfilzomib comes from the randomised (1:1), open-label, phase III ARROW trial of 578 patients with relapsed and refractory multiple myeloma with measurable disease who had received two or three prior treatments (including a proteasome inhibitor and immunomodulatory imide drug ie lenalidomide or thalidomide) (<a href=\"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext\" target=\"_blank\">Moreau et al. Lancet Oncol. 2018;19:953-64</a>). The Subcommittee noted that the ARROW population were more heavily pre-treated and disease-refractory than the ENDEAVOR population.</p><p><br></p><p>1.14.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that participants received carfilzomib 70 mg/m<sup>2</sup> once weekly (20 mg/m\u00b2 day 1 cycle 1; 70 mg/m\u00b2 thereafter) or carfilzomib 27 mg/m<sup>2</sup> twice weekly (20 mg/m\u00b2 days 1 and 2 during cycle 1; 27 mg/m\u00b2 thereafter). The Subcommittee noted that all patients received dexamethasone 40 mg on days 1, 8, 15 (all cycles) and 22 (cycles 1\u20139 only) and that the 28-day treatment cycles continued until disease progression or unacceptable toxicity.</p><p>1.14.2.<span style=\"font-size: 7pt;\"> </span>The Subcommittee considered that the lower dose carfilzomib comparator was less relevant and that a twice weekly standard dose (ie 56 mg/m<sup>2</sup> twice weekly as per ENDEAVOR and Medsafe approved dose) would have been more relevant to the New Zealand population.</p><p>1.14.3.<span style=\"font-size: 7pt;\"> </span>The Subcommittee noted that the primary endpoint was PFS in the intention-to-treat population, which was median 11.2 months (95% CI 8.6 to 13.0) with 70 mg/m<sup>2</sup> once weekly vs 7.6 months (95% CI: 5.8 to 9.2) with 27 mg/m<sup>2</sup> twice weekly (HR 0.69, 95% CI: 0.54 to 0.83; <i>P</i>=0.0029).</p><p>1.14.4.<span style=\"font-size: 7pt;\"> </span>The Subcommittee noted that median PFS was greater with 56 mg/m<sup>2</sup> twice-weekly in ENDEAVOR (18.7 months) than with 70 mg/m<sup>2</sup> once-weekly in ARROW (11.3 months), however, data with propensity score adjustment suggested there was more benefit with the ARROW regimen (median PFS 21.0 months) compared with ENDEAVOR (14.9 months). The Subcommittee noted that, due to the lack of non-inferiority or superiority testing, CaTSoP previously considered in <a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">October 2019</a> that these high-dose once-weekly and twice-weekly regimens likely provided comparable PFS benefits. </p><p>1.14.5.<span style=\"font-size: 7pt;\"> </span>The Subcommittee considered it likely that a population with fewer prior lines of treatment (eg more akin to the ENDEAVOR population) would receive a greater PFS benefit than that reported for ARROW participants from the once-weekly 70 mg/m<sup>2</sup> ARROW regimen.</p><p><span style=\"color: black;\">1.15.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted further evidence of once-weekly carfilzomib dosing comes from the abstract of a phase II trial (GEM-KyCyDex) presented at the December 2020 ASH conference <a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\" style=\"color: windowtext;\">(</a><a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\">Mateos et al. 415 Paper presented at: American Society of Haematology Annual Meeting; December 2020</a><a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\" style=\"color: windowtext;\">).</a><a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\" style=\"color: rgb(0, 176, 80);\"> </a>The Subcommittee noted that 198 participants received carfilzomib 70mg/m<sup>2</sup> (days 1,8,15) and dexamethasone 20mg (days 1,8,15) with or without cyclophosphamide IV 300mg/m2 (days 1,8, 15).</p><p>1.15.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the median age was 70 years and that 61% of participants received one prior line of treatment. The Subcommittee noted that all patients had previously been treated with bortezomib, that about 90% responded to bortezomib treatment and approximately 70% had been previously treated with lenalidomide, half of who had refractory disease. </p><p>1.15.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the reporting that after median follow-up of 15.6 months, median PFS was 20.7 months with carfilzomib, dexamethasone and cyclophosphamide vs 15.2 months carfilzomib and dexamethasone (<i>P</i>=0.2). The Subcommittee considered that it was expected that cyclophosphamide would add benefit, especially in <span style=\"color: black;\">immunomodulatory imide drug</span>-refractory patients where there was a significant benefit in PFS (26.2 months vs 7.7 months; <i>P</i>=0.01). The Subcommittee considered that this supported the evidence of effect from once-weekly carfilzomib in the ARROW trial. </p><p>\tEvidence for carfilzomib with dexamethasone and lenalidomide (second-line) </p><p><span style=\"color: black;\">1.16.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted evidence from the randomised (1:1), open-label, multicentre, phase III ASPIRE study, which included 792 patients with relapsed multiple myeloma with measurable disease (<a href=\"https://www.nejm.org/doi/10.1056/NEJMoa1411321?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov\" target=\"_blank\">Stewart et al. N Engl J Med. 2015;372:142-52</a>; <a href=\"https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7\" target=\"_blank\">Dimopoulos et al. J Hematol Oncol. 2018;11:49</a>). The Subcommittee noted that 43% of participants had received one prior line of therapy and 65% had two to three prior lines. The Subcommittee noted that 65% of participants had received prior bortezomib and 20% prior lenalidomide, although the trial did not include patients who were refractory to these agents. </p><p>1.16.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that participants received carfilzomib twice weekly (20 mg/m<sup>2</sup> days 1 and 2 of cycle 1; 27 mg/m<sup>2</sup> thereafter until progression or unacceptable toxicity; omitted on D8 and D9 during cycles 13 to 18; and discontinued after 18 cycles) with lenalidomide (25 mg days 1-21) and dexamethasone (40 mg days 1, 8, 15 and 22) or lenalidomide with dexamethasone (control group) according to the same dosing. </p><p>1.16.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the primary endpoint was PFS in the intention-to-treat population, which was median 26.3 months (95% CI: 23.3 to 30.5) with carfilzomib vs 17.6 months (95% CI: 15.0 to 20.6) in the control group (HR for progression or death, 0.69; 95% CI, 0.57 to 0.83; <i>P</i>=0.0001).</p><p>1.16.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that this evidence indicates a benefit from carfilzomib in the carfilzomib group with lenalidomide and that hazard ratios for PFS in subgroups suggest most subgroups appear to benefit from treatment (eg according to number of prior lines, prior bortezomib use or not). The Subcommittee considered that this data suggests the carfilzomib regimen could be considered effective in the second-line or third-line setting.</p><p>Summary</p><p><span style=\"color: black;\">1.17.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee considered that the evidence supporting a benefit of carfilzomib for patients with relapsed/refractory multiple myeloma was stronger for patients who had received only one prior line of treatment, compared with patients with multiply relapsed disease. The Subcommittee also considered that the unmet need for patients at initial relapse was greater, given the current treatment options available, than the unmet need in multiply relapsed patients.</p><p><span style=\"color: black;\">1.18.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that quality of life (QOL) from the addition of carfilzomib in ENDEAVOR treatment was similar to QOL with bortezomib and dexamethasone (<a href=\"https://www.nature.com/articles/s41408-019-0181-0\" target=\"_blank\">Ludwig et al. Blood Cancer J. 2019;9:23</a>); that QOL data in ARROW indicated a preference for once-weekly treatment (<a href=\"https://www.nature.com/articles/s41375-019-0480-2\" target=\"_blank\">Moreau et al. Leukemia. 2019;33:2934-46</a>); and that ASPIRE suggested that QOL with carfilzomib, lenalidomide and dexamethasone was as good or better than QOL with lenalidomide and dexamethasone alone (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27601539/\" target=\"_blank\">Stewart et al. J Clin Oncol. 2016;34:3921-30</a>). The Subcommittee considered all carfilzomib QOL outcomes were similar, indicating that carfilzomib is well tolerated, that it does not negatively impact quality of life, and that weekly dosing is preferred. </p><p><span style=\"color: black;\">1.19.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that there was no direct comparative evidence for carfilzomib 70 mg/m<sup>2</sup> once weekly vs 56 mg/m<sup>2</sup> twice weekly, and that it was reasonable to assume that the differences between ENDEAVOR and ARROW patients reflect the extent of pre-treatment in these groups. The Subcommittee considered that the evidence for carfilzomib once-weekly and twice-weekly dosing was of good strength and quality. Overall, the Subcommittee considered this evidence suggests carfilzomib once weekly would provide benefits in the second-line and in the third-line setting, and that the evidence from ENDEAVOR and ASPIRE suggests the benefit would be across all subgroups with relapsed/refractory MM (although there would be smaller benefit in lenalidomide-refractory disease). </p><p><span style=\"color: black;\">1.20.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that the higher carfilzomib doses given once weekly were equivalent to dosing of 70 mg/m2 and 112 mg/m2 per week and that these regimens are used in some jurisdictions (registered in USA and Switzerland; being considered by TGA and Canada). The Subcommittee considered it reasonable to infer that efficacy is probably similar between these two dosing regimens and that risks may be similar, although weekly treatment may be slightly better tolerated. </p><p><span style=\"color: black;\">1.21.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee considered that, if funded as a second-line or third-line treatment, carfilzomib and dexamethasone could be administered either according to the ENDEAVOR trial dosing (56 mg/m<sup>2</sup> twice weekly) or the ARROW trial dosing (70 mg/m<sup>2</sup> once weekly) until disease progression. The Subcommittee noted that in <a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">October 2019</a> CaTSoP had thought that the uptake of 70 mg/m<sup>2</sup> once weekly would be low, given uncertainty of benefit. The Subcommittee considered that the updated publication with evidence of impact from once-weekly dosing, along with the submission from the NZMIG indicating that this dosing regimen would be preferred by New Zealand clinicians, suggests that once-weekly may be preferred due to its lesser impact on infusion resources. The Subcommittee considered that the higher weekly dosing may be used in patients who find the twice-weekly treatment challenging eg due to travel requirements and infusion burden.</p><p><span style=\"color: black;\">1.22.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee considered that it would be reasonable to assume that the outcomes observed with twice-weekly carfilzomib in the ENDEAVOR trial would be similar if these patients had received the once-weekly dosing regimen used in the ARROW trial. The Subcommittee therefore considered that it would be reasonable to use the outcomes from each trial as a surrogate for the benefit of carfilzomib-based therapy at initial relapse or in multiply relapsed patients.</p><p> </p><p><i>General</i></p><p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that there was no randomised controlled trial evidence comparing second-line treatment options against each other (ie carfilzomib vs pomalidomide) therefore evidence was lacking to inform preferred treatment sequencing. However, the Subcommittee considered that there would be a preference for carfilzomib to be used second-line, with pomalidomide reserved for third-line or later use. The Subcommittee noted that it will consider an <a href=\"https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000BD0yw/p001671\" target=\"_blank\">application for subcutaneous daratumumab</a> at a future meeting and that the Subcommittee could again indicate the preferred treatment options for this population at that time.\u00a0</p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that it would be reasonable to target funding via Special Authority criteria to enable carfilzomib and pomalidomide each to be used once per patient lifetime, or to be used in pre-specified treatment lines, as supported by evidence.</p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the estimate that 50% of patients with multiple myeloma may be eligible for transplant. However, the Subcommittee considered this estimate was likely too high for second- or third-line patients, as transplant eligibility decreases over time given the age of patients at initial diagnosis. The Subcommittee considered that in time, the funded use of lenalidomide in the relapsed/refractory setting would be indicative of the proportion of patients who are ineligible for transplant in third-line setting. The Subcommittee noted that there are approximately 400 patients diagnosed with multiple myeloma each year and considered that approximately 50% would initially be eligible for transplant. The Subcommittee considered that on this basis there would be approximately 130 patients who would relapse post-transplant each year; that there would be approximately 150 patients who would relapse after first line treatment if ineligible for transplant each year; and there would be approximately 170 patients who would require treatment in the third line setting each year.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the number of cycles received will depend on PFS which is influenced by prior lines of therapy and the proportion of patients whose disease was refractory, therefore the treatment cost per cycle would be most useful for cost-effectiveness assessment, as opposed to cost per treatment, given the variable extent of pre-treatment in the clinical trials.</p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that for second-line treatment, comparators could be bortezomib retreatment as CyBorD/BTD, or MPT and CTD. The Subcommittee considered that the key outcome of interest in this setting was improved PFS (above that gained from bortezomib retreatment). The Subcommittee considered the most appropriate comparator for use in the second-line would be BTD, unless the patient could not tolerate bortezomib, in which case regimens without bortezomib would be used. The Subcommittee considered that the efficacy of thalidomide in this setting is limited by the development of neuropathy, and efficacy difficult to establish from the scientific evidence base as most studies use more novel agents at relapse. The Subcommittee considered that outcomes would be expected to be worse without bortezomib.</p><p><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that for third-line treatment, standard therapy is lenalidomide and dexamethasone with or without bortezomib, although patients who had a prior autologous stem cell transplant with lenalidomide maintenance could be considered for third-line treatment with a bortezomib and/or thalidomide-based regimen. The Subcommittee considered that the key outcomes of interest in this setting were improved PFS and OS. </p><h2><br></h2>",
          "change": null
        },
        "Published_Application": {
          "s": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that Pharmac sought further advice from the Subcommittee regarding pomalidomide and carfilzomib in the relapsed/refractory setting for multiple myeloma, and that this advice was requested in the context of:</p><p>1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>A supplier submission received in February 2021 from Celgene for pomalidomide for relapsed/refractory multiple myeloma (second-line and third-line); </p><p>1.1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>Correspondence from members of the New Zealand Myeloma Interest Group [NZMIG]).</p><h2><br></h2>",
          "fs": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that Pharmac sought further advice from the Subcommittee regarding pomalidomide and carfilzomib in the relapsed/refractory setting for multiple myeloma, and that this advice was requested in the context of:</p><p>1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>A supplier submission received in February 2021 from Celgene for pomalidomide for relapsed/refractory multiple myeloma (second-line and third-line); </p><p>1.1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>Correspondence from members of the New Zealand Myeloma Interest Group [NZMIG]).</p><h2><br></h2>",
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "Medium",
          "fs": "Medium",
          "change": null
        },
        "Links": {
          "s": "<p><a href=\"https://pharmac.govt.nz/assets/2021-04-12-Cancer-Treatment-Record.pdf\" target=\"_blank\" style=\"font-size: 14px; background-color: rgb(255, 255, 255);\">Cancer Treatments Subcommittee records</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/assets/2021-04-12-Cancer-Treatment-Record.pdf\" target=\"_blank\" style=\"font-size: 14px; background-color: rgb(255, 255, 255);\">Cancer Treatments Subcommittee records</a></p>",
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2021",
          "fs": "Aug 2021",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Monday 12 April 2021.",
          "fs": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Monday 12 April 2021.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hmGTUAY"
          },
          "Id": "a0P2P000006hmGTUAY",
          "Event_Date__c": "2021-08-03",
          "Event_Description__c": "Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Monday 12 April 2021.",
          "Stage__c": "Seeking Clinical Advice",
          "Links__c": "<p><a href=\"https://pharmac.govt.nz/assets/2021-04-12-Cancer-Treatment-Record.pdf\" target=\"_blank\" style=\"font-size: 14px; background-color: rgb(255, 255, 255);\">Cancer Treatments Subcommittee records</a></p>",
          "Outcome__c": "Medium",
          "Formatted_Date__c": "Aug 2021",
          "Published_Recommendation__c": "<p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span></p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The evidence for a PFS benefit with carfilzomib compared with bortezomib in this setting, and the evidence of an OS benefit in this setting from the ENDEAVOR trial; and</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That it was reasonable to extrapolate the benefits observed in the ENDEAVOR trial to the ARROW trial noting the different levels of prior treatment in these populations.<a href=\"\" target=\"_blank\" style=\"font-size: 8pt;\">[LH1]</a><span style=\"font-size: 8pt;\">\u00a0</span></p><p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee <b>recommended</b> that carfilzomib (once-weekly) for the third-line treatment of relapsed or refractory multiple myeloma be funded with a <b>medium</b> <b>priority</b>, in the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">CARFILZOMIB</b></p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Initial application</b><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\"> \u2013 (relapsed/refractory multiple myeloma) only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">All of the following:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">1.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Patient has relapsed or refractory multiple myeloma with progressive disease; and</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">2.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Patient has received two prior lines of treatment; and</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">3.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Treatment to be administered in combination with dexamethasone.</span></p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">\u00a0</b></p><p><b style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Renewal</b><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\"> - (relapsed/refractory multiple myeloma) only from a haematologist or any other medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">Both:</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">1.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">No evidence of disease progression; and</span></p><p><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">2.</span><span style=\"color: rgb(34, 34, 34); font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 9pt;\">The treatment remains appropriate and patient is benefitting from treatment.</span></p><p>1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>In making this recommendation, the Subcommittee considered</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The high health need of patients with relapsed/refractory multiple myeloma (including lenalidomide-refractory disease) requiring third-line treatment, however that the need for treatment in this setting was less than that in first relapse; and</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The evidence for a PFS benefit with carfilzomib compared with bortezomib in this setting, and the evidence of an OS benefit in this setting from the ENDEAVOR trial; and</p><p>-<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>That it was reasonable to extrapolate the benefits observed in the ENDEAVOR trail to the ARROW trial noting the different levels of prior treatment in these populations.</p><p> </p>",
          "Published_Application__c": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that Pharmac sought further advice from the Subcommittee regarding pomalidomide and carfilzomib in the relapsed/refractory setting for multiple myeloma, and that this advice was requested in the context of:</p><p>1.1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>A supplier submission received in February 2021 from Celgene for pomalidomide for relapsed/refractory multiple myeloma (second-line and third-line); </p><p>1.1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>Correspondence from members of the New Zealand Myeloma Interest Group [NZMIG]).</p><h2><br></h2>",
          "Published_Discussion__c": "<p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that, based on real-world clinical practice, almost all patients with multiple myeloma will receive first-line treatment although only about 61% and 38% of patients will receive second- and third-line treatments, respectively. </p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the possible second-line treatment options consisted of bortezomib retreatment (as CyBorD/BTD) or bortezomib in combination with melphalan and prednisone (BMP) and that it was preferable to expose patients to new agents than retreating with bortezomib. Alternatively, patients would receive a thalidomide-based regimen, which would consist of cyclophosphamide, thalidomide and dexamethasone (CTD) or melphalan, prednisone and thalidomide (MPT), all for approximately six to 12 cycles. The Subcommittee noted that patients could be eligible for lenalidomide in combination with dexamethasone until progression if neuropathy prevents use of bortezomib and thalidomide-based regimens. The Subcommittee noted that in patients with relapsed/refractory multiple myeloma, if remission was for greater than two to three years, and the patient was transplant eligible, a second autologous stem cell transplant would be offered.</p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the choice of second-line regimen would be determined by the duration of response to first-line treatment, toxicities experienced in the first-line, and patient-specific factors including the desire for oral therapy.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that once a patient progresses after second line therapy, if they had received an autologous stem cell transplant with lenalidomide maintenance there are no further options for this patient group. The Subcommittee noted that lenalidomide with dexamethasone with or without bortezomib was a third-line treatment option, only for transplant-ineligible patients who had not received lenalidomide maintenance post autologous stem cell transplant. </p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee was made aware of data reporting progression-free survival (PFS) of around eight months with bortezomib retreatment in relapsed multiple myeloma, from two clinical trials, and considered the efficacy of bortezomib retreatment after first-line bortezomib to be limited: </p><p><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>A 6.5-month duration of response was reported in 130 patients who received bortezomib with or without dexamethasone after median two prior lines of therapy (<a href=\"https://doi.org/10.1111/bjh.12198\" target=\"_blank\">Petrucci et al. Br J Haematol. 2013;160:649-59</a>); and </p><p><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>In the CASTOR trial control arm of bortezomib and dexamethasone (N = 113), median PFS was 7.1 months and median PFS in patients who had received one prior line of therapy was 7.9 months. About 45% of patients had received one prior line, and about 70% of patients had prior bortezomib exposure (<a href=\"http://www.haematologica.org/content/103/12/2079.long\" target=\"_blank\">Spencer et al. Haematologica. 2018;103:2079-87</a>).</p><p><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the duration of benefit from thalidomide in the second-line setting was hard to estimate, as clinical trials generally allow use of agents at relapse that are less comparable to the New Zealand setting, however, noted that thalidomide is associated with relatively short PFS and toxicities including neuropathy which limit its use. The Subcommittee considered it reasonable to assume that outcomes would be similar to that observed in patients retreated with bortezomib.</p><p><span style=\"color: black;\">1.7.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee was made aware of evidence that a significant number of patients (about 50%) progress on lenalidomide maintenance and have few subsequent treatment options, as they are unlikely to receive a response from thalidomide and early relapse after prior bortezomib treatment makes its use in retreatment less likely to be successful (<a href=\"https://ashpublications.org/blood/article/134/Supplement_1/1779/427686/Outcomes-in-Multiple-Myeloma-Patients-Progressing\" target=\"_blank\">Sanchez et al. Blood. 2019;134(Suppl_1):1779</a>). </p><p><span style=\"color: black;\">1.8.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that in New Zealand the second-line treatment options provide suboptimal benefits and that there is a definite need for more effective second-line treatment for multiple myeloma including lenalidomide-refractory patients. The Subcommittee considered the unmet need for treatments in later lines of therapy was also high, but that the number of patients requiring treatment in this context was less, and that there would be a proportion of patients who would remain eligible for lenalidomide-based treatment in this setting.</p><p><span style=\"color: black;\">1.9.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that multiple myeloma treatment is evolving internationally with use of other combinations and other treatments, and was made aware of international clinical guidelines that recommend second-line treatments or combinations that are not funded in New Zealand (<a href=\"https://jnccn.org/doi/10.6004/jnccn.2018.0002\" target=\"_blank\">Kumar et al. J Natl Compr Canc Netw. 2018;16:11-20</a>; <a href=\"https://linkinghub.elsevier.com/retrieve/pii/3768071\" target=\"_blank\">Moreau et al. Ann Oncol. 2017;28(suppl_4):iv52-iv61</a>). The Subcommittee noted that some of the potential treatments that could be used by patients with relapsed/refractory multiple myeloma include, but are not limited to carfilzomib, ixazomib, pomalidomide, daratumumab and elotuzumab.</p><p><span style=\"color: black;\">1.10.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that the New Zealand Myeloma Interest Group (NZMIG) has expressed its preference for daratumumab (especially if subcutaneous) and carfilzomib, which the NZMIG consider very effective, to be funded for the treatment of relapsed/refractory multiple myeloma. However, the Subcommittee noted that Pharmac sought advice at this time regarding carfilzomib and pomalidomide in the context of currently funded treatments (ie without consideration of unfunded treatments such as daratumumab).<a href=\"\" target=\"_blank\" style=\"font-size: 8pt;\">[LH1]</a><span style=\"font-size: 8pt;\">\u00a0</span></p><p><i>Carfilzomib</i></p><p><span style=\"color: black;\">1.11.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that it had previously reviewed an application for carfilzomib in the relapsed/refractory setting in <a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">October 2019</a> following PTAC\u2019s review of the application in <a href=\"https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf\" target=\"_blank\">February 2019</a>. The Subcommittee noted that carfilzomib is an intravenously-administered proteasome inhibitor and that Medsafe has approved carfilzomib (Kyprolis) in combination with either lenalidomide and dexamethasone, or dexamethasone alone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. The Subcommittee noted that the Medsafe data sheet lists the following recommended dosing regimens for carfilzomib in this setting: </p><p>1.11.1.<span style=\"font-size: 7pt;\"> </span>Carfilzomib (with dexamethasone) administered as a 20 mg/m<sup>2</sup> starting dose, then on cycle 1 day 8, if tolerated, carfilzomib dose increased to 70 mg/m<sup>2</sup> once weekly (30-minute infusion); and</p><p>1.11.2.<span style=\"font-size: 7pt;\"> </span>Carfilzomib (with dexamethasone and lenalidomide) administered as a 20 mg/m<sup>2</sup> starting dose, then on cycle 1 day 8, if tolerated, carfilzomib dose increased to 27 mg/m<sup>2</sup> twice weekly (10-minute infusion) or 56 mg/m<sup>2</sup> twice weekly (30-minute infusion).</p><p><span style=\"color: black;\">1.12.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that international funding bodies in Australia, Canada, England and Wales, and Scotland have recommended carfilzomib in combination with dexamethasone be funded for second-line use (and for third-line use in Canada). The Subcommittee noted that the once-weekly regimen is funded in Australia for patients with relapsed/refractory multiple myeloma.</p><p>Evidence for carfilzomib with dexamethasone (second-line and third-line) </p><p><span style=\"color: black;\">1.13.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that evidence for twice-weekly carfilzomib comes from the randomised (1:1), phase III, open-label, multicentre ENDEAVOR trial of 929 patients with relapsed or refractory multiple myeloma (<a href=\"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00464-7/fulltext\" target=\"_blank\">Dimopoulos et al. Lancet Oncol. 2016;17:27-38</a>). The Subcommittee noted that the median age of ENDEAVOR participants was 65 years and considered this group was slightly younger than New Zealand patient population who are about 70 years at diagnosis. The Subcommittee noted that participants had one to three (median two) prior lines of therapy, with half of participants in each group having received two or three prior lines, and 54% of participants having previously received bortezomib.</p><p>1.13.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that participants received carfilzomib 56 mg/m<sup>2 </sup>twice weekly (20 mg/m<sup>2</sup> on days one and two of cycle one; 56 mg/m<sup>2</sup> thereafter) with dexamethasone (20 mg oral or intravenous [IV] infusion) or bortezomib (1.3 mg/m<sup>2</sup>; IV bolus or subcutaneous [SC] injection) with dexamethasone as 28-day cycles continued until disease progression. The Subcommittee noted that this dosing was one of the Medsafe-approval regimens and considered that the bortezomib comparator treatment was a relevant treatment option in the New Zealand setting, although triple therapy may also be used. </p><p>1.13.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the primary endpoint was progression-free survival (PFS) in the intention-to-treat population, which was a median 18.7 months (95% CI 15.6\u2013not estimable) with carfilzomib versus 9.4 months (8.4\u201310.4) with bortezomib (hazard ratio, HR 0.53; 95% CI: 0.44 to 0.65; P&lt;0.0001). The Subcommittee noted that PFS in patients previously exposed to bortezomib was 15.6 months (12.9 to not evaluable) with carfilzomib vs 8.1 months (6.6 to 9.5) with bortezomib. The Subcommittee considered that the outcomes in the control arm of this trial were indicative of the outcomes that could be expected with bortezomib retreatment.</p><p>1.13.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that carfilzomib was favoured over bortezomib retreatment in all patient subgroups except patients with disease refractory to prior bortezomib or lenalidomide, although there were small patient numbers in those groups.</p><p>1.13.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the pre-planned interim overall survival (OS) analysis was performed at cut-off date Jan 3, 2017, at which time the median OS was 47.6 months (95% CI 42.5-not evaluable) with carfilzomib versus 40.0 months (32.6-42.3) in the bortezomib group (HR 0.791 [95% CI 0.648-0.964], one-sided <i>P</i>=0.010) (<a href=\"https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(17)30578-8\" target=\"_blank\">Dimopoulos et al. Lancet Oncol. 2017;18:1327-37</a>). The Subcommittee noted that there was less OS benefit in patients over 75 years of age, those with renal impairment (creatine clearance &lt;30 mL/min) and those with high-risk cytogenetics.</p><p><span style=\"color: black;\">1.14.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that evidence for once-weekly carfilzomib comes from the randomised (1:1), open-label, phase III ARROW trial of 578 patients with relapsed and refractory multiple myeloma with measurable disease who had received two or three prior treatments (including a proteasome inhibitor and immunomodulatory imide drug ie lenalidomide or thalidomide) (<a href=\"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30354-1/fulltext\" target=\"_blank\">Moreau et al. Lancet Oncol. 2018;19:953-64</a>). The Subcommittee noted that the ARROW population were more heavily pre-treated and disease-refractory than the ENDEAVOR population.</p><p><br></p><p>1.14.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that participants received carfilzomib 70 mg/m<sup>2</sup> once weekly (20 mg/m\u00b2 day 1 cycle 1; 70 mg/m\u00b2 thereafter) or carfilzomib 27 mg/m<sup>2</sup> twice weekly (20 mg/m\u00b2 days 1 and 2 during cycle 1; 27 mg/m\u00b2 thereafter). The Subcommittee noted that all patients received dexamethasone 40 mg on days 1, 8, 15 (all cycles) and 22 (cycles 1\u20139 only) and that the 28-day treatment cycles continued until disease progression or unacceptable toxicity.</p><p>1.14.2.<span style=\"font-size: 7pt;\"> </span>The Subcommittee considered that the lower dose carfilzomib comparator was less relevant and that a twice weekly standard dose (ie 56 mg/m<sup>2</sup> twice weekly as per ENDEAVOR and Medsafe approved dose) would have been more relevant to the New Zealand population.</p><p>1.14.3.<span style=\"font-size: 7pt;\"> </span>The Subcommittee noted that the primary endpoint was PFS in the intention-to-treat population, which was median 11.2 months (95% CI 8.6 to 13.0) with 70 mg/m<sup>2</sup> once weekly vs 7.6 months (95% CI: 5.8 to 9.2) with 27 mg/m<sup>2</sup> twice weekly (HR 0.69, 95% CI: 0.54 to 0.83; <i>P</i>=0.0029).</p><p>1.14.4.<span style=\"font-size: 7pt;\"> </span>The Subcommittee noted that median PFS was greater with 56 mg/m<sup>2</sup> twice-weekly in ENDEAVOR (18.7 months) than with 70 mg/m<sup>2</sup> once-weekly in ARROW (11.3 months), however, data with propensity score adjustment suggested there was more benefit with the ARROW regimen (median PFS 21.0 months) compared with ENDEAVOR (14.9 months). The Subcommittee noted that, due to the lack of non-inferiority or superiority testing, CaTSoP previously considered in <a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">October 2019</a> that these high-dose once-weekly and twice-weekly regimens likely provided comparable PFS benefits. </p><p>1.14.5.<span style=\"font-size: 7pt;\"> </span>The Subcommittee considered it likely that a population with fewer prior lines of treatment (eg more akin to the ENDEAVOR population) would receive a greater PFS benefit than that reported for ARROW participants from the once-weekly 70 mg/m<sup>2</sup> ARROW regimen.</p><p><span style=\"color: black;\">1.15.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted further evidence of once-weekly carfilzomib dosing comes from the abstract of a phase II trial (GEM-KyCyDex) presented at the December 2020 ASH conference <a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\" style=\"color: windowtext;\">(</a><a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\">Mateos et al. 415 Paper presented at: American Society of Haematology Annual Meeting; December 2020</a><a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\" style=\"color: windowtext;\">).</a><a href=\"https://ash.confex.com/ash/2020/webprogram/Paper140934.html\" target=\"_blank\" style=\"color: rgb(0, 176, 80);\"> </a>The Subcommittee noted that 198 participants received carfilzomib 70mg/m<sup>2</sup> (days 1,8,15) and dexamethasone 20mg (days 1,8,15) with or without cyclophosphamide IV 300mg/m2 (days 1,8, 15).</p><p>1.15.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the median age was 70 years and that 61% of participants received one prior line of treatment. The Subcommittee noted that all patients had previously been treated with bortezomib, that about 90% responded to bortezomib treatment and approximately 70% had been previously treated with lenalidomide, half of who had refractory disease. </p><p>1.15.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the reporting that after median follow-up of 15.6 months, median PFS was 20.7 months with carfilzomib, dexamethasone and cyclophosphamide vs 15.2 months carfilzomib and dexamethasone (<i>P</i>=0.2). The Subcommittee considered that it was expected that cyclophosphamide would add benefit, especially in <span style=\"color: black;\">immunomodulatory imide drug</span>-refractory patients where there was a significant benefit in PFS (26.2 months vs 7.7 months; <i>P</i>=0.01). The Subcommittee considered that this supported the evidence of effect from once-weekly carfilzomib in the ARROW trial. </p><p>\tEvidence for carfilzomib with dexamethasone and lenalidomide (second-line) </p><p><span style=\"color: black;\">1.16.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted evidence from the randomised (1:1), open-label, multicentre, phase III ASPIRE study, which included 792 patients with relapsed multiple myeloma with measurable disease (<a href=\"https://www.nejm.org/doi/10.1056/NEJMoa1411321?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov\" target=\"_blank\">Stewart et al. N Engl J Med. 2015;372:142-52</a>; <a href=\"https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7\" target=\"_blank\">Dimopoulos et al. J Hematol Oncol. 2018;11:49</a>). The Subcommittee noted that 43% of participants had received one prior line of therapy and 65% had two to three prior lines. The Subcommittee noted that 65% of participants had received prior bortezomib and 20% prior lenalidomide, although the trial did not include patients who were refractory to these agents. </p><p>1.16.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that participants received carfilzomib twice weekly (20 mg/m<sup>2</sup> days 1 and 2 of cycle 1; 27 mg/m<sup>2</sup> thereafter until progression or unacceptable toxicity; omitted on D8 and D9 during cycles 13 to 18; and discontinued after 18 cycles) with lenalidomide (25 mg days 1-21) and dexamethasone (40 mg days 1, 8, 15 and 22) or lenalidomide with dexamethasone (control group) according to the same dosing. </p><p>1.16.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that the primary endpoint was PFS in the intention-to-treat population, which was median 26.3 months (95% CI: 23.3 to 30.5) with carfilzomib vs 17.6 months (95% CI: 15.0 to 20.6) in the control group (HR for progression or death, 0.69; 95% CI, 0.57 to 0.83; <i>P</i>=0.0001).</p><p>1.16.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that this evidence indicates a benefit from carfilzomib in the carfilzomib group with lenalidomide and that hazard ratios for PFS in subgroups suggest most subgroups appear to benefit from treatment (eg according to number of prior lines, prior bortezomib use or not). The Subcommittee considered that this data suggests the carfilzomib regimen could be considered effective in the second-line or third-line setting.</p><p>Summary</p><p><span style=\"color: black;\">1.17.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee considered that the evidence supporting a benefit of carfilzomib for patients with relapsed/refractory multiple myeloma was stronger for patients who had received only one prior line of treatment, compared with patients with multiply relapsed disease. The Subcommittee also considered that the unmet need for patients at initial relapse was greater, given the current treatment options available, than the unmet need in multiply relapsed patients.</p><p><span style=\"color: black;\">1.18.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that quality of life (QOL) from the addition of carfilzomib in ENDEAVOR treatment was similar to QOL with bortezomib and dexamethasone (<a href=\"https://www.nature.com/articles/s41408-019-0181-0\" target=\"_blank\">Ludwig et al. Blood Cancer J. 2019;9:23</a>); that QOL data in ARROW indicated a preference for once-weekly treatment (<a href=\"https://www.nature.com/articles/s41375-019-0480-2\" target=\"_blank\">Moreau et al. Leukemia. 2019;33:2934-46</a>); and that ASPIRE suggested that QOL with carfilzomib, lenalidomide and dexamethasone was as good or better than QOL with lenalidomide and dexamethasone alone (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27601539/\" target=\"_blank\">Stewart et al. J Clin Oncol. 2016;34:3921-30</a>). The Subcommittee considered all carfilzomib QOL outcomes were similar, indicating that carfilzomib is well tolerated, that it does not negatively impact quality of life, and that weekly dosing is preferred. </p><p><span style=\"color: black;\">1.19.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that there was no direct comparative evidence for carfilzomib 70 mg/m<sup>2</sup> once weekly vs 56 mg/m<sup>2</sup> twice weekly, and that it was reasonable to assume that the differences between ENDEAVOR and ARROW patients reflect the extent of pre-treatment in these groups. The Subcommittee considered that the evidence for carfilzomib once-weekly and twice-weekly dosing was of good strength and quality. Overall, the Subcommittee considered this evidence suggests carfilzomib once weekly would provide benefits in the second-line and in the third-line setting, and that the evidence from ENDEAVOR and ASPIRE suggests the benefit would be across all subgroups with relapsed/refractory MM (although there would be smaller benefit in lenalidomide-refractory disease). </p><p><span style=\"color: black;\">1.20.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee noted that the higher carfilzomib doses given once weekly were equivalent to dosing of 70 mg/m2 and 112 mg/m2 per week and that these regimens are used in some jurisdictions (registered in USA and Switzerland; being considered by TGA and Canada). The Subcommittee considered it reasonable to infer that efficacy is probably similar between these two dosing regimens and that risks may be similar, although weekly treatment may be slightly better tolerated. </p><p><span style=\"color: black;\">1.21.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee considered that, if funded as a second-line or third-line treatment, carfilzomib and dexamethasone could be administered either according to the ENDEAVOR trial dosing (56 mg/m<sup>2</sup> twice weekly) or the ARROW trial dosing (70 mg/m<sup>2</sup> once weekly) until disease progression. The Subcommittee noted that in <a href=\"https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-10.pdf\" target=\"_blank\">October 2019</a> CaTSoP had thought that the uptake of 70 mg/m<sup>2</sup> once weekly would be low, given uncertainty of benefit. The Subcommittee considered that the updated publication with evidence of impact from once-weekly dosing, along with the submission from the NZMIG indicating that this dosing regimen would be preferred by New Zealand clinicians, suggests that once-weekly may be preferred due to its lesser impact on infusion resources. The Subcommittee considered that the higher weekly dosing may be used in patients who find the twice-weekly treatment challenging eg due to travel requirements and infusion burden.</p><p><span style=\"color: black;\">1.22.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Subcommittee considered that it would be reasonable to assume that the outcomes observed with twice-weekly carfilzomib in the ENDEAVOR trial would be similar if these patients had received the once-weekly dosing regimen used in the ARROW trial. The Subcommittee therefore considered that it would be reasonable to use the outcomes from each trial as a surrogate for the benefit of carfilzomib-based therapy at initial relapse or in multiply relapsed patients.</p><p> </p><p><i>General</i></p><p><span style=\"color: black;\">1.1.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted that there was no randomised controlled trial evidence comparing second-line treatment options against each other (ie carfilzomib vs pomalidomide) therefore evidence was lacking to inform preferred treatment sequencing. However, the Subcommittee considered that there would be a preference for carfilzomib to be used second-line, with pomalidomide reserved for third-line or later use. The Subcommittee noted that it will consider an <a href=\"https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000BD0yw/p001671\" target=\"_blank\">application for subcutaneous daratumumab</a> at a future meeting and that the Subcommittee could again indicate the preferred treatment options for this population at that time.\u00a0</p><p><span style=\"color: black;\">1.2.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that it would be reasonable to target funding via Special Authority criteria to enable carfilzomib and pomalidomide each to be used once per patient lifetime, or to be used in pre-specified treatment lines, as supported by evidence.</p><p><span style=\"color: black;\">1.3.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee noted the estimate that 50% of patients with multiple myeloma may be eligible for transplant. However, the Subcommittee considered this estimate was likely too high for second- or third-line patients, as transplant eligibility decreases over time given the age of patients at initial diagnosis. The Subcommittee considered that in time, the funded use of lenalidomide in the relapsed/refractory setting would be indicative of the proportion of patients who are ineligible for transplant in third-line setting. The Subcommittee noted that there are approximately 400 patients diagnosed with multiple myeloma each year and considered that approximately 50% would initially be eligible for transplant. The Subcommittee considered that on this basis there would be approximately 130 patients who would relapse post-transplant each year; that there would be approximately 150 patients who would relapse after first line treatment if ineligible for transplant each year; and there would be approximately 170 patients who would require treatment in the third line setting each year.</p><p><span style=\"color: black;\">1.4.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that the number of cycles received will depend on PFS which is influenced by prior lines of therapy and the proportion of patients whose disease was refractory, therefore the treatment cost per cycle would be most useful for cost-effectiveness assessment, as opposed to cost per treatment, given the variable extent of pre-treatment in the clinical trials.</p><p><span style=\"color: black;\">1.5.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that for second-line treatment, comparators could be bortezomib retreatment as CyBorD/BTD, or MPT and CTD. The Subcommittee considered that the key outcome of interest in this setting was improved PFS (above that gained from bortezomib retreatment). The Subcommittee considered the most appropriate comparator for use in the second-line would be BTD, unless the patient could not tolerate bortezomib, in which case regimens without bortezomib would be used. The Subcommittee considered that the efficacy of thalidomide in this setting is limited by the development of neuropathy, and efficacy difficult to establish from the scientific evidence base as most studies use more novel agents at relapse. The Subcommittee considered that outcomes would be expected to be worse without bortezomib.</p><p><span style=\"color: black;\">1.6.</span><span style=\"color: black; font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Subcommittee considered that for third-line treatment, standard therapy is lenalidomide and dexamethasone with or without bortezomib, although patients who had a prior autologous stem cell transplant with lenalidomide maintenance could be considered for third-line treatment with a bortezomib and/or thalidomide-based regimen. The Subcommittee considered that the key outcomes of interest in this setting were improved PFS and OS. </p><h2><br></h2>",
          "Status_History__c": "a132P000000D4JwQAK"
        },
        "change": null
      }
    ],
    "dateString": "Feb 2019",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Aug 2021",
          "fs": "Aug 2021",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hmGUUAY"
          },
          "Id": "a0P2P000006hmGUUAY",
          "Event_Date__c": "2021-08-27",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "Aug 2021",
          "Status_History__c": "a132P000000D7kpQAC"
        },
        "change": null
      }
    ],
    "dateString": "Aug 2021",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": null,
    "dateString": null,
    "collapsed": false,
    "checked": false
  }
]